KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Operating Expenses (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Other Operating Expenses data on record, last reported at $339.7 million in Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 26.27% year-over-year to $339.7 million; the TTM value through Dec 2025 reached $1.7 billion, up 58.21%, while the annual FY2025 figure was $2.1 billion, 94.44% up from the prior year.
  • Other Operating Expenses reached $339.7 million in Q3 2025 per JAZZ's latest filing, down from $1.4 billion in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.4 billion in Q2 2025 and bottomed at $108.4 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $363.5 million, with a median of $283.4 million recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: plummeted 74.79% in 2021, then soared 418.13% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $293.4 million in 2021, then surged by 131.64% to $679.8 million in 2022, then plummeted by 59.28% to $276.8 million in 2023, then rose by 3.91% to $287.6 million in 2024, then grew by 18.13% to $339.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $339.7 million in Q3 2025, $1.4 billion in Q2 2025, and $287.6 million in Q4 2024.